Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2013

Date: September 20, 2013
Pages: 100
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O23EFA6A9C2EN
Leaflet:

Download PDF Leaflet

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2013
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Onychomycosis (Tinea Unguium).
  • A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) Overview
Therapeutics Development
An Overview of Pipeline Products for Onychomycosis (Tinea Unguium)
Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Onychomycosis (Tinea Unguium) Therapeutics - Products under Development by Companies
Companies Involved in Onychomycosis (Tinea Unguium) Therapeutics Development
Watson Pharmaceuticals, Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Kaken Pharmaceutical Co.,Ltd.
NexMed, Inc.
NovaBay Pharmaceuticals, Inc.
Nuvo Research Inc.
Hisamitsu Pharmaceutical Co., Inc.
Evolva SA
Novabiotics Ltd
Anacor Pharmaceuticals, Inc.
Nitric Biotherapeutics, Inc.
NanoBio Corporation
Moberg Derma AB
Viamet Pharmaceuticals, Inc.
Celtic Pharmaceutical Holdings L.P.
Mayne Pharma Limited
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HB-1275 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efinaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efinaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tavaborole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN-2718 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOB-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
silver dihydrogen citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ME-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycobactovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onychomycosis (Tinea Unguium) Therapeutics - Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics - Discontinued Products
Onychomycosis (Tinea Unguium) Therapeutics - Dormant Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Jul 29, 2013: Anacor Pharmaceuticals Announces That It Has Submitted a New Drug Application to the FDA for Tavaborole
Jul 18, 2013: Anacor Pharmaceuticals to Present Pivotal Phase 3 Data of Tavaborole for the Topical Treatment of Toenail Onychomycosis
Jun 12, 2013: Topica Pharma Completes Enrollment For Phase IIb/III Onychomycosis Trial Of 10% Luliconazole Solution
May 29, 2013: Anacor Pharma Successfully Completes Pre-NDA Communications With FDA For Tavaborole
May 28, 2013: FDA Rejects NDA For Valeant Pharma's Efinaconazole As Treatment For Onychomycosis
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015
May 14, 2013: Hisamitsu Pharma Announces Positive Phase II Trial Results Of Terbinafine Hydrochloride Patch For Treatment Of Tinea Unguium
May 02, 2013: Anacor Pharma Provides Update Regarding Arbitration With Valeant Pharma
Feb 28, 2013: Anacor Pharma Announces Positive Results From Second Phase III Trial Of Tavaborole For Onychomycosis
Jan 29, 2013: Anacor Pharma Announces Positive Results From First Of Two Phase III Trials Of Tavaborole For Onychomycosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Onychomycosis (Tinea Unguium), H2 2013
Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Watson Pharmaceuticals, Inc., H2 2013
Eisai Co., Ltd., H2 2013
Helix BioMedix, Inc., H2 2013
Kaken Pharmaceutical Co.,Ltd., H2 2013
NexMed, Inc., H2 2013
NovaBay Pharmaceuticals, Inc., H2 2013
Nuvo Research Inc., H2 2013
Hisamitsu Pharmaceutical Co., Inc., H2 2013
Evolva SA, H2 2013
Novabiotics Ltd, H2 2013
Anacor Pharmaceuticals, Inc., H2 2013
Nitric Biotherapeutics, Inc., H2 2013
NanoBio Corporation, H2 2013
Moberg Derma AB, H2 2013
Viamet Pharmaceuticals, Inc., H2 2013
Celtic Pharmaceutical Holdings L.P., H2 2013
Mayne Pharma Limited, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Onychomycosis (Tinea Unguium) Therapeutics - Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics - Discontinued Products
Onychomycosis (Tinea Unguium) Therapeutics - Dormant Products

LIST OF FIGURES

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2013
Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

COMPANIES MENTIONED

Watson Pharmaceuticals, Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Kaken Pharmaceutical Co.,Ltd.
NexMed, Inc.
NovaBay Pharmaceuticals, Inc.
Nuvo Research Inc.
Hisamitsu Pharmaceutical Co., Inc.
Evolva SA
Novabiotics Ltd
Anacor Pharmaceuticals, Inc.
Nitric Biotherapeutics, Inc.
NanoBio Corporation
Moberg Derma AB
Viamet Pharmaceuticals, Inc.
Celtic Pharmaceutical Holdings L.P.
Mayne Pharma Limited
Tinea Pedis - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 28 pages
Tinea Corporis - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 24 pages
Tinea Corporis – Pipeline Review, H1 2012 US$ 500.00 May, 2012 · 20 pages
Myasthenia Gravis - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 51 pages

Ask Your Question

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: